Nebula Research & Development’s SpringWorks Therapeutics SWTX Stock Holding History

Nebula Research & Development’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,385	Closed	-$458K	–	1148
2025 Q1	$458K	Sell	10,385 -14,635	-58%	-$674K	0.04%	630
2024 Q4	$904K	Sell	25,020 -6,996	-22%	-$244K	0.11%	328
2024 Q3	$1.03M	Buy	32,016 +25,124	+365%	+$939K	0.12%	282
2024 Q2	$260K	Buy	+6,892	New	+$290K	0.04%	650
2024 Q1	–	Sell	-8,850	Closed	-$323K	–	991
2023 Q4	$323K	Buy	+8,850	New	+$231K	0.1%	412

Other funds holding SWTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Nebula Research & Development's SWTX Position: Q2 2025 in Review

Nebula Research & Development sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 10,385 shares — an estimated $458K sold.

Nebula Research & Development first reported a position in SWTX in Q4 2023 and held it in 5 quarters. The position peaked at $1.03M in Q3 2024. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

Nebula Research & Development reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
Nebula Research & Development sold 10,385 SpringWorks Therapeutics shares in Q2 2025, an estimated $458K.
Nebula Research & Development first reported a position in SpringWorks Therapeutics in Q4 2023 and held it in 5 quarters.
Nebula Research & Development's SpringWorks Therapeutics position peaked at $1.03M in Q3 2024.
222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Nebula Research & Development's 13F filing for Q2 2025, filed 14 Aug 2025.